electroCore, Inc.
NASDAQ:ECOR

Watchlist Manager
electroCore, Inc. Logo
electroCore, Inc.
NASDAQ:ECOR
Watchlist
Price: 16.26 USD -7.19% Market Closed
Market Cap: 106.5m USD
Have any thoughts about
electroCore, Inc.?
Write Note

electroCore, Inc.
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

electroCore, Inc.
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
electroCore, Inc.
NASDAQ:ECOR
Operating Income
-$13m
CAGR 3-Years
15%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Operating Income
$2.9B
CAGR 3-Years
7%
CAGR 5-Years
6%
CAGR 10-Years
6%
Boston Scientific Corp
NYSE:BSX
Operating Income
$2.9B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
11%
Stryker Corp
NYSE:SYK
Operating Income
$4.8B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
8%
Abbott Laboratories
NYSE:ABT
Operating Income
$7B
CAGR 3-Years
-7%
CAGR 5-Years
10%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Operating Income
$2.1B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

electroCore, Inc.
Glance View

Market Cap
105.8m USD
Industry
Health Care

electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).

ECOR Intrinsic Value
18.49 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

What is electroCore, Inc.'s Operating Income?
Operating Income
-13m USD

Based on the financial report for Sep 30, 2024, electroCore, Inc.'s Operating Income amounts to -13m USD.

What is electroCore, Inc.'s Operating Income growth rate?
Operating Income CAGR 5Y
24%

Over the last year, the Operating Income growth was 39%. The average annual Operating Income growth rates for electroCore, Inc. have been 15% over the past three years , 24% over the past five years .

Back to Top